Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CANCER

Financiado

Cerrado

Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improvi...

Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art f... ver más

31/08/2023

PERC

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

PERCUROS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

MSCA-RISE-2017: Research and Innovation Staff Excha... Objective:The RISE scheme will promote international and inter-sector collaboration through research...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

PERC

378.00K€ | Lider

HEL2

162.00K€ | Participante

Progredum GmbH

108.00K€ | Participante

HELRIK

N.D. | Participante

Proyectos interesantes

ISPIC

Medical Technol...

Nanotechnology

4M€ Cerrado

MultiTheranostic

Medical Technol...

Nanotechnology

Financiado

RTC2019-006809-1

Medical Technol...

Nanotechnology

583K€ Cerrado

Melomanes

Medical Technol...

Nanotechnology

Financiado

SAF2014-54057-R

Medical Technol...

Nanotechnology

242K€ Cerrado

ONCOTHERANOSTICS

Nanotechnology

Medical Technol...

257K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 69 meses Fecha Inicio: 2017-11-21
Fecha Fin: 2023-08-31

Líder del proyecto

PERCUROS BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions. This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project: i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a lifetime of protection against cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores